<DOC>
	<DOCNO>NCT03088670</DOCNO>
	<brief_summary>To demonstrate efficacy Gosogliptin Monotherapy Combination Metformin non-inferior efficacy Vildagliptin Monotherapy combination Metformin effect glycosilated hemoglobin ( HbA1c ) Week 12 Week 36 compare baseline ( Week 0 ) .</brief_summary>
	<brief_title>Efficacy Safety Gosogliptin Monotherapy Combination With Metformin vs. Vildagliptin Monotherapy Combination With Metformin Drug-naive Type 2 Diabetic Patients .</brief_title>
	<detailed_description>- Screening patient Week -2 - Training comply patient Diabetes Program School Week -1 glucometer patient diary distribution SMBG - Randomization one two group ratio 1:1 . - The 1st stage include 12 week monotherapy Gosogliptin Vildagliptin . - The 2nd stage include 24 week combination therapy Gosogliptin Metformin Vildagliptin Metformin . - Follow-up period 4 week .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>1 . Men woman 18 78 year 2 . Confirmed clinical diagnosis type 2 diabetes mellitus 3 . Drugnaive patient patient without hypoglycemic drug treatment least till 12 week screen 4 . Patient 's agree use adequate method contraception study 5 . Body mass index 2240 kg/m2 6 . HbA1c 7.5 11.0 % 7 . FPG &lt; 15 mmol/L 8 . Signed informed consent 9 . Patient 's ability follow protocol requirement 1 . Pregnancy lactation , woman plan become pregnant clinical study , woman childbearing potential ( i.e . nonstylized surgically period post menopause less 2 year ) without adequate method contraception . 2 . History type 1 diabetes mellitus form 3 . Severe metabolic complication diabetes ketoacidosis , hyperosmolar coma 6 week screen 4 . Severe complication diabetes , instance proliferative retinopathy active stage , autonomic neuropathy gastroparesis 5 . A known allergy , hypersensitivity contraindication Gosogliptin , Vildagliptin , Metformin components 6 . Convulsive disorder ; system autoimmune disease vascular collagenosis demand previous current treatment systemic corticosteroid , cytostatics ; malignancy within last 5 year ( except basalcell carcinoma ) ; 7 . Significant cardiovascular disease within 12 month screen include : chronic heart failure class III IV ( NYHA ) , severe arrhythmia demand treatment antiarrhythmic , unstable angina , myocardial infarction , heart coronary vessel surgery , heart valve disease , transitory ischaemic attack stroke , uncontrolled arterial hypertension systolic Blood Pressure &gt; 180 mm Hg diastolic Blood Pressure &gt; 110 mm Hg , pulmonary embolism deep venous thrombosis 8 . A nephrotic syndrome , chronic renal failure , serum creatinine &gt; 1.5 mg/dL ( 132 µmol/L ) men &gt; 1.4 mg/dL ( 123 µmol/L ) woman GFR &lt; 60 ml/min/1.73m2 9 . HBV , HCV liver cirrhosis ; AST ALT &gt; 3 ULN ; total bilirubin &gt; 2 ULN 10 . HIV ; severe infection affect glycemia within 30 day screen 11 . Anemia ( Hb ≤10.5 g/dL woman ≤11.5 g/dL men ) ; loss &gt; 1 unit blood ( 500 mL ) blood transfusion within 12 week screen 12 . Drugs alcohol abuse 13 . Administration study drug within 30 day screen 14 . Inability read write ; unwillingness understand follow protocol procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>78 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>